12:10-13:40	Innovation in Endometriosis Treatment Sponsored by Bayer Schering Pharma AG
Chairpersons	F. Petraglia, Italy C. Petta, Brazil
12:10-12:15	Introduction F. Petraglia, Italy
12:15-12:30	Living with endometriosis L. Hummelshøj, UK
12:30-12:50	Treatment considerations in managing endometriosis S. Kennedy, UK
12:50-13:05	New evidence-based treatment in endometriosis L. Kiesel, Germany
13:05-13:30	Pharmacological insights into the efficacy of Visanne® D. Hornung, Germany
13:30-13:40	Implications for clinical practice C. Petta, Brazil
13:40-14:30	Lunch break

14:30-16:00	Androgen Restored Contraception Sponsored by an unrestricted grant from Pantarhei Bioscience B.V.
Capsule	Combined oral contraceptives (COCs) reduce androgen and especially free testosterone (T) levels considerably. Is it possible to restore this iatrogenic androgen deficiency by the addition of DHEA and what are the clinical implications?
Chairpersons	H.J.T. Coelingh Bennink, Netherlands Z. Ben-Rafael, Israel
	The endocrinology B. Fauser, Netherldands
	The sex R.H.W. van Lunsen, Netherldands
	The benefits J-M. Foidart, Belgium
Objectives	Upon completion of these sessions, the audience will learn:
	* The magnitude of the effect of COCs on androgen levels * The effect of adding DHEA on androgen levels * The clinical benefits of restoration of androgen levels during COC use
16:00-16:30	Coffee break

16:30-18:00	What is in the Pipeline for Hypoactive Sexual Desire Disorders (HSDD)?
Capsule	The complexity of female sexual response probably explains why HSDD, that includes physical, psychological and hormonal factors, was found to be so common. Despite being common, controversy on diagnosis and treatment continues. According to the 1999 AMA survey, over 40% of women are affected, complaining mainly of low sexual desire, difficulty reaching orgasm, insufficient lubrication and painful coitus. While local lubricants, estrogens and systemic estrogens and androgens may be helpful in certain situations, the need to develop the armamentarium to cover other causes of HSDD is clear. What can we expect in coming years?
Chairperson	J-M. Foidart, Belgium J. Studd, UK
	Debate: Should HSDD be Medically Treated? Proposition: Sexuality of women is complex, diagnosis is unclear, and treatments fail to meet expectations J. Bitzer, Switzerland Opposition: Treatments should be individualized when symptoms cause distress A. Graziottin, Italy Discussion
	Testosterone always with estrogens? A.R. Genazzani, Italy
	Understanding the neurobiology of desire, SSRIs, Flibanserin J. Bitzer, Switzerland
Objectives	To acquire knowledge about the following:
	* Classification and prevalence of HSDD * The differences in etiology of SD * Clinical efficacy and safety of testosterone * New SERM's and SSRI's desvenlafaxine bazedoxifene, lasofoxifene

Saturday, November 6, 2010

08:30-10:00	Endoscopy Sponsored by an unrestricted grant from KARL STORZ GmbH & Co. KG
Capsule	Instruments are refined and indications for endoscopic operations seem to be ever-expanding: What are the limits? Experts views on cutting edge procedures
Chairpersons	P. Koninckx, Belgium V. Gomel, Canada
08:30-08:52	Office hysteroscopy: Is the 'see and treat philosophy' correct? S. Bettocchi, Italy
08:52-09:14	Operative hysteroscopy, what is the limit? J. Hamou, France
09:14-09:36	S-PORTAL: Single port surgery also in gynecology? L. Mereu, Italy
09:36-10:00	Should we only be performing laparoscopic hysterectomy? What are the limits? J. Donnez, Belgium
Objectives:	Upon completion of these sessions, the audience will learn:
	* The indications and limitations of office and operative hysteroscopy * Indications and limitations of laparoscopic hysterectomy
10:00-10:20	Coffee break

10:20-11:50	Selective Estrogen Receptor Modulators (SERM's): Present and Future Sponsored by a restricted grant from DAIICHI SANKYO EUROPE GmbH
Capsule	The ideal SERM prevents osteoporotic fractures, decreases risk, and improves cardiovascular risk, with no or minimal side effects: Where do we stand today?
Chairpersons	S. Palacios, Spain P. Hadji, Germany
	Current SERM's: Clinical overview and results P. Hadji, Germany
	Debate: SERM's: The Future of Menopausal Treatment? Proposition: Raloxifene is a class on its own for prevention and treatment of osteoporosis and the future of SERM's is bright! J. Calaf-Alsina, Spain Opposition: Current and new SERM's are facing some better alternatives F.A. Tremollieres, France Discussion
	Selection of Patients for SERM's Treatment C. De Geyter, Switzerland
Objectives	To acquire knowledge of the following:
	* Clinical trials with Raloxifene * New SERM’s approved : Lasofoxifene and Bazedoxifene * The benefit and safety of SERM's * Which SERM for which patient?
11:50-12:10	Poster viewing

12:10-13:40	Epithelial Ovarian Cancer (I): Can Survival be Improved through Early Detection and Triage? Sponsored by an unrestricted grant from Fujirebio Diagnostics Inc.
Capsule	Early diagnosis of ovarian cancer can improve survival!
Chairpersons	R.G. Moore, USA R. Kreienberg, Germany
	Ovarian cancer screening in the general population: The use of biomarkers and imaging R.C. Bast Jr, USA
	Ovarian cancer screening in the BRCA and familial ovarian cancer patients A. Rosenthal, UK
	Identifying women at high risk for epithelial ovarian cancer with ovarian cysts or pelvic masses R.G. Moore, USA
Objectives	Upon completion of this debate, the audience will learn:
	* Screening strategies for ovarian cancer * Screening strategies for women at high risk for ovarian cance
13:30-14:30	Lunch break

14:30-16:00	Epithelial Ovarian Cancer (II): The Place of Biomarkers and Imaging in the Management of Ovarian Cancer Sponsored by an unrestricted grant from Abbott Diagnostics Inc.
Capsule	No agreement exists as to the most effective way in which to follow-up patients with epithelial ovarian cancer
Chairperson	R.G. Moore, USA M. Markman, USA
	Debate: Should Biomarkers be used Routinely for the Monitoring of Epithelial Ovarian Cancer? Yes: R.C. Bast Jr, USA No: A. Rosenthal, UK Discussion
	Imaging should be used for monitoring patients with epithelial ovarian cancer W. Meier, Germany
Objectives	Upon completion of this debate, the audience will learn:
	* The use of biomarkers for monitoring ovarian cancer patients * The use of imaging in monitoring ovarian cancer patients * Combined use of biomarkers and imaging for ovarian cancer monitoring
16:00-16:30	Coffee break

16:30-18:00	Deep Endometriosis
Capsule	Deep endometriosis deserves special attention and thorough understanding! However, no agreement exists on the optimal diagnosis and of this special types of endometriosis
Chairperson	S. Kennedy, UK
	Is endometriosis an inflammatory disease? P. Florio, Italy
	Debate: Diagnosing Deep Endometriosis: Should we be Satisfied with Current Methods? Proposition: Imaging is the best method for diagnosis of deep endometriosis! S. Kennedy, UK Opposition: Biomarkers are the future for diagnosis of endometriosis! L. Kiesel, Germany Discussion
Objectives:	* Shortcomings of current diagnostic methods * Why we need newer diagnostic tools * The advantages and shortcomings of 'noninvasive' diagnostic * Current understanding of the pathophysiology

Friday, November 5, 2010 (second hall)

08:30-10:00	Operative Procedures: Tricks of the Trade
Capsule	Results of surgery depend on choosing the right procedure for the right patient, and recognizing the pitfalls and risks of the operation. Good results also depend on a meticulous technique. How can all these be improved?
Chairpersons	V. Gomel, Canada M.P. Brincat, Malta
	Can we reduce or prevent adhesions during intrauterine manipulation? Techniques and pitfalls J. Hamou, France
	How to reduce the risk of future fertility during myomectomy procedure Techniques and pitfalls P. Koninckx, Belgium
	Creation of a neovagina: Techniques and pitfalls L. Adamyan, Russia
Objectives	Upon completion of this session, the audience will learn :
	* How to reduce Intrauterine adhesions during uterine manipulation * How to reduce mechanical infertility "Post myomectomy" * A new technique for creation of a Neovagina
10:00-10:20	Coffee break

10:20-11:50	Future and Novel Treatments for Epithelial Ovarian Cancers
Capsule	Despite all the improvements survival rate of patients with epithelial ovarian cancer is still poor. Can new treatments improve survival?
Chairpersons	R.G. Moore, USA A. Rosenthal, UK
	Heated intraperitoneal chemotherapy (HIPC) for the treatment of carcinomatosis of the abdominal and pelvic cavities T. Miner, USA
	Treatment of metastatic ovarian cancer by active immunization against zona pellucida antigens H.J.T. Coelingh Bennink, Netherlands
	Avastin and other biologics for the treatment of epithelial ovarian cancer M. Markman, USA
Objectives	Upon completion of this debate, the audience will learn :
	* What new treatments are available for ovarian cancer * The potential future treatments for ovarian cancer * Use of biologics for the treatment of ovarian cancer
11:50-12:10	Poster viewing
12:10-13:40	Join Hall A or B
13:40-14:30	Lunch break

14:30-16:00	Epithelial Ovarian Cancer: Current Standards of Care
Capsule	Adjuvant chemotherapy is a mainstay of ovarian cancer treatment. Recent data suggest that intraperitoneal chemotherapy may be superior to standard i.v. chemotherapy following cytoreductive surgery
Chairpersons	R. Kreienberg, Germany T.J. Miner, USA
	Counter-views/Debate: Intraperitoneal Chemotherapy Intraperitoneal chemotherapy should be the first choice for adjuvant treatment of epithelial ovarian cancer R.G. Moore, USA Consolidation chemotherapy should be standard of care for epithelial ovarian cancer patients M. Markman, USA Discussion
	Neoadjuvant Chemotherapy for ovarian cancer - Pro and Con U. Wagner, Germany
Objectives	Upon completion of this debate, the audience will learn:
	* Whether or not intraperitoneal chemotherapy for ovarian cancer is better than i.v. application. If so, in which patients *) Whether neoadjuvant (primary) chemotherapy followed by interval cytoreductive surgery is better than surgery followed by chemotherapy. If so, in which patient group *) The place of consolidation chemotherapy
16:00-16:30	Coffee break

16:30-18:00	Breast Cancer
Capsule	Breast cancer occurring during the reproductive years requires understanding of the various management options
Chairpersons	M. Thill, Germany W. Jonat, Germany
	Estetrol as HRT for women with breast cancer A. Graziottin, Italy
	Fertility preservation in women with breast cancer G. Griesinger, Germany
	Cancer and pregnancy W. Jonat, Germany

Saturday, November 6, 2010 (second hall)

08:30-10:00	Breast Cancer From Bench to Bedside: Translational Research in Oncology
Chairpersons	S. Becker, Germany W. Jonat, Germany
	Molecular pathology and predictive biomarkers for therapy response in breast cancer C. Denkert, Germany
	Circulating tumor cells for optimization of breast cancer treatment T. Fehm, Germany
	Update – hereditary breast cancer S. Becker, Germany
10:00-10:20	Coffee break

10:20-11:50	Cervical Cancer and Human Papilloma Virus (HPV)
Capsule	Does vaccination mark the end of cervical cancer?
Chairpersons	X. Bosch, Spain R. Moore, USA
Discussants	M. Hampl, Germany A.M. Kaufmann, Germany P. Benedetti Panici, Italy
	Hot Controversies – Experts’ Opinions on:
	* The difference between quadrivalent or bivalent HPV vaccine * The efficacy of vaccination in adolescents and women over 30 years of age * How long immunization provides immunity * Whether current knowledge implies immunization against cancer, or merely precancerous stages * Whether we are certain that vaccination prevents all cervical cancers * Whether vaccination is cost-effective * Protection of vaccines against other HPV subtypes, as well as HPV 16 and 18, and whether there is cross reactivity * The ages to be considered for vaccination * If there is concern that migration to other types of HPV will become the main cause of HPV-related cervical cancer * Whether males should be vaccinated * Whether the Pap smear is obsolete in immunized patients * Whether HPV-DNA typing Is still needed * Routine inclusion of colposcopy in a pelvic examination. If so, how often? * Should we give booster after 10 years? * Should vaccination be withheld from HPV positive women?
11:50-12:10	Poster viewing

12:10-13:40	Endometrial Cancer
Capsule	Pelvic and para-aortic lymphadenectomy (LNE) is part of the FIGO staging system. Recent prospective, randomized trials suggest that LNE may not improve survival in endometrial cancer. For decades external beam pelvic radiotherapy has been used as an adjuvant therapy in endometrial cancer. Recent randomized trials suggest that this approach does not improve survival
Chairpersons	W. Lichtenegger, Germany G. Emons, Germany
	Debate: Role of Lymphadenectomy for Endometrial Cancer Pro: G. Emons, Germany Con: P. Benedetti Panici, Italy Discussion
	Debate: Role of Radiotherapy for Endometrial Cancer Pro: S. Marnitz–Schultze, Germany Con: W. Lichtenegger, Germany Discussion

Objectives	Upon completion of this debate, the audience will learn:
	* Whether LNE has a therapeutic effect in endometrial cancer * If so, in which patients? * Whether LNE is beneficial in directing adjuvant therapy * Whether or not external beam pelvic radio therapy improves local control in EC patients and is better than vaginal brachy therapy? * Does it improve overall or disease specific survival? * Are multimodal adjuvant strategies more efficacious than radiotherapy?
13:40-14:30	Lunch break

14:30-16:00	Postmenopausal Osteoporosis
Capsule	The usual patients with low bone mineral density and fracture risk who are seen by a gynecologist are often younger than 65 years, while research on drugs is undertaken on women over this age
Chairpersons	S.O. Skouby, Denmark S. Rozenberg, Belgium
	Debate: Should we Treat Women with Low Bone Mineral Density who are Younger than 65 Years, and How? Proposition: Evidence for the effectiveness of drugs at this age is lacking, and treatment is not cost-effective P. Hadji, Germany Opposition: There is enough experience to manage these patients, but therapy should be individualized C. Christiansen, Denmark Discussion
	Should premenopausal women with osteoporosis be tested and treated? S. Palacios, Spain

Objectives	* DEXA indication * Risk factors and prevalence of osteoporotic fractures in women over 65 years * Fracture index in this age group * Risk factors and prevalence of osteoporotic fractures in premenopausal women
13:40-14:30	Coffee break

16:30-18:30	Hormone Replacement Therapy (HRT), Quo Vadis?
Capsule	Women's Health Initiative (WHI) has brought about a sharp decline in hormone replacement therapy (HRT/HT) in asymptomatic and symptomatic women. A key criticism of WHI is the age of the population selected, which is well above the critical age window where HT is still expected to prevent (if at all) cardiovascular disease (CVD)
Chairpersons	A.R. Genazzani, Italy C. Christiansen, Denmark
	HRT - Should all menopausal women with metabolic syndrome be treated? J.C. Stevenson, UK
	Debate: Is There Evidence for an HT critical window to Prevent Disease? Yes: S.O. Skouby, Denmark No: S. Rozenberg, Belgium Discussion
	Panel Discussion Discussant: S.O. Skouby, Denmark J.C. Stevenson, UK S. Rozenberg, Belgium P. Hadji, Germany S. Palacios, Spain Questions: * Should we continue treating well-informed, asymptomatic women? * Should HT be considered as the first choice for all climacteric symptoms? * Should HT be a choice in young menopausal women with mild osteoporosis? * For how long should HT be given in symptomatic women? * Should all women with early menopause be offered treatment with HT? * Should androgens be added to HT? To whom? What are the perils? * Where should we go from here? * Is hot flushes benign or predictor of Neurological vulnerability

Objectives	Upon completion of this debate, the audience will learn:
	* Whether HT can prevent CVD * About the critical window, and what proof there is of its existence * Whether it is still customary to prescribe HT, and to whom? * If HT is a must in premature menopause? * The place of androgens in HT * Metabolic syndrome and the menopause